Genmab Wins Scrip's Biotech Company of the Year Award

Summary:  Genmab has won the 2007 Scrip Biotech Company of the Year award.      

Copenhagen, Denmark; December 5, 2007 - Genmab A/S (OMX: GEN) announced today it
has won the 2007 Scrip Biotech Company of the Year award.  The award was        
presented December 4, 2007 at an awards ceremony and gala dinner at the London  
Hilton on Park Lane hotel.                                                      

The award recognizes Genmab's accomplishments during 2006 and 2007 including our
work to bring new products closer to their first markets, raise capital, enter  
significant licensing agreements, maintain strong management, address unmet     
medical needs through development of our new technology UniBody(R) and to       
transform Genmab from an early stage to a more mature world leading             
biotechnology company.                                                          

“Receiving the Scrip Award is a testament to the skill and efficiency of all    
Genmab employees who have worked hard to make our business grow.  We are        
delighted to have won and are honored to receive this year's Scrip Award for    
Biotech Company of the Year,” said Lisa N. Drakeman, Ph.D., Chief Executive     
Officer at Genmab.  
                                                            
About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using unique,       
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.   
As Genmab advances towards a commercial future, we remain committed to our      
primary goal of improving the lives of patients who are in urgent need of new   
treatment options.  For more information on Genmab's products and technology,   
visit www.genmab.com.                                                           

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);   
and UniBody(R) are all trademarks of Genmab A/S.                                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Investor News No. 16/2007                                                       

###